Skip to content

Does Provision of Point of Care CD4 Technology and Early Knowledge of CD4 Levels Affect Early Initiation and Retention on Anti-retroviral Treatment (ART) in HIV Positive Pregnant Women in the Context of Option B+ for PMTCT?

Does Provision of Point of Care CD4 Technology and Early Knowledge of CD4 Levels Affect Early Initiation and Retention on Anti-retroviral Treatment (ART) in HIV Positive Pregnant Women in the Context of Option B+ for PMTCT?

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02070900
Acronym
E4E
Enrollment
704
Registered
2014-02-25
Start date
2014-01-31
Completion date
2016-07-31
Last updated
2014-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS

Keywords

Prevention of Mother to Child Transmission, PMTCT, Option B+, ART, Retention, Loss to Follow Up, Time to initiation, POC CD4, Clinical mentoring, Costing, HIV, AIDS, Zimbabwe

Brief summary

The study will be conducted at 32 health care facilities in three provinces in Zimbabwe and will compare the impact of the provision Point of Care CD4 technology and early knowledge of CD4 levels on retention at 12 months, with or without POC CD4 and a programmatic mentoring package. Option B+ will be implemented at all sites and 16 intervention sites will receive POC CD4 machines and visits from a team of clinical mentors. The study also aims to assess rates of ART initiation and time to ART initiation of HIV positive pregnant women in settings implementing option B+ with or without POC CD4 and related counselling/support; rates of retention in care of HIV positive mothers at 6 months post ART initiation in settings implementing option B+ with or without POC CD4 and related counselling/support; rates of ART initiation and retention at 6 and 12 months post ART initiation according to different levels of CD4 count; cost of retaining HIV positive pregnant women until 6 and 12 months; acceptability and feasibility of POC CD4 as an adjunct to good clinical care of HIV positive pregnant women.

Interventions

DEVICEPOC CD4

Point of Care device for CD4 count testing (to be used as a clinical monitoring tool)

OTHERProgrammatic Mentoring

Programmatic Mentoring aimed at messaging around CD4 count to encourage retention on lifelong ART for PMTCT patients, administered by trained clinical mentors

Sponsors

Canadian International Development Agency
CollaboratorOTHER_GOV
Netherlands: Ministry of Health, Welfare and Sports
CollaboratorOTHER_GOV
WHO, Department of Maternal, Newborn, Child and Adolescent Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
Yes

Inclusion criteria

* Pregnant at the time of booking * HIV positive diagnosis * Not on ART at the time of booking * Present up to 38 weeks into gestation * Presents more than 48 hours prior to delivery

Exclusion criteria

* Already on ART at booking * Presents more than 38 weeks into gestation or less than 48 hours prior to delivery

Design outcomes

Primary

MeasureTime frameDescription
Retention12 monthsProportion of HIV positive pregnant women that are retained on ART, 12 months after initiation

Secondary

MeasureTime frameDescription
Time-to-initiation12 monthsMedian time-to-initiation between HIV positive diagnosis and enrolment onto Option B+ with or without POC CD4 and related counseling/support
Retention at 6 months6 monthsProportion of HIV positive pregnant women that are retained on ART, 6 months after initiation in settings implementing option B+ with or without POC CD4 and related counseling/support
Retention by CD4 count6 months , 12 monthsProportion of women initiated and retained on ART at 6 and 12 months post ART initiation, according to different levels of CD4 count
Cost per pregnant woman retained on ART6 months , 12 months
Initiation within 1 month1 monthProportion of HIV positive pregnant women initiating ART within 1 month of positive HIV test

Countries

Zimbabwe

Contacts

Primary ContactAlexio Z Mangwiro
amangwiro@clintonhealthaccess.org

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026